MTN-042/DELIVER – A Phase IIIb open-label study designed to evaluate the safety and acceptability of the monthly dapivirine vaginal ring, which is under regulatory review, and Truvada as daily PrEP in pregnant women. The study, which launched in South Africa in early 2020, will enroll 750 women at different times during pregnancy who will use either the dapivirine ring or Truvada as PrEP until they deliver. Women will be followed for six weeks postpartum, and their babies will be followed for one year. Other trial sites are in Malawi, Uganda and Zimbabwe. The study is the first of the ring in pregnant women and will provide more insight about the safety of Truvada as PrEP during pregnancy, a time when women are at much greater risk of HIV.
Questions and Answers - The DELIVER and B-PROTECTED Studies
21-July-2021
10,000-plus medical charts provides comparator for HIV prevention study in pregnant women
31-March-2021
Fact Sheet: The MTN-042B Sub-study of DELIVER (MTN-042)
31-March-2021
The DELIVER and B-PROTECTED Studies: Preventing HIV in Pregnant and Breastfeeding Women
08-September-2020
Researchers launch DELIVER study to assess safety of PrEP and dapivirine vaginal ring in pregnant women
10-February-2020
Video about DELIVER and B-PROTECTED in English
Video about DELIVER and B-PROTECTED in Zulu
Video about DELIVER and B-PROTECTED in Luganda
Video about DELIVER and B-PROTECTED in Shona
Video about DELIVER and B-PROTECTED in Chichewa
See Also
MTN-042 Study Page
Meeting Report: Stakeholders Consultation on MTN-042
MTN-043 (B-PROTECTED) Study Page